Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Moodys
Baxter
McKesson
Colorcon

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for LY3314814

See Plans and Pricing

« Back to Dashboard

Drug Development Status for LY3314814: Sponsors, patents, clinical trial progress

LY3314814 is an investigational drug.

There have been 12 clinical trials for LY3314814. The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2017.

The most common disease conditions in clinical trials are Alzheimer Disease, Dementia, and Renal Insufficiency. The leading clinical trial sponsors are Eli Lilly and Company, AstraZeneca, and [disabled in preview].

There are five US patents protecting this investigational drug and sixty international patents.

Recent Clinical Trials for LY3314814
TitleSponsorPhase
A Study of LY3314814 in Participants With Liver ImpairmentAstraZenecaPhase 1
A Study of LY3314814 in Participants With Liver ImpairmentEli Lilly and CompanyPhase 1
A Study of Lanabecestat in Healthy Female Participants Taking Oral ContraceptiveAstraZenecaPhase 1

See all LY3314814 clinical trials

Clinical Trial Summary for LY3314814

Top disease conditions for LY3314814
Top clinical trial sponsors for LY3314814

See all LY3314814 clinical trials

US Patents for LY3314814

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LY3314814   Start Trial Compounds and their use as BACE inhibitors AstraZeneca AB (Sodertalje, SE)   Start Trial
LY3314814   Start Trial Compounds and their use as BACE inhibitors AstraZeneca AB (Sodertalje, SE)   Start Trial
LY3314814   Start Trial Compounds and their use as BACE inhibitors Astrazeneca AB (Sodertalje, SE)   Start Trial
LY3314814   Start Trial Compounds and their use as BACE inhibitors ASTRAZENECA AB (Sodertalje, SE)   Start Trial
LY3314814   Start Trial Compounds and their use as BACE inhibitors ASTRAZENECA AB (Sodertalje, SE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LY3314814

Drugname Country Document Number Estimated Expiration Related US Patent
LY3314814 Argentina 084553 2030-12-22   Start Trial
LY3314814 Argentina 107709 2030-12-22   Start Trial
LY3314814 Australia 2011345389 2030-12-22   Start Trial
LY3314814 Australia 2016200538 2030-12-22   Start Trial
LY3314814 Australia 2017261475 2030-12-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Dow
Express Scripts
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.